Coherus BioSciences (CHRS) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.35 +9.76%
EPS Growth %: +39.4%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +39.4%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.34), in-line with the analyst estimate of ($0.34). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $14.16 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Fold Holdings (FLD) files for 51.23M share offering by selling stockholders
- Teva shares Phase 3 data on once-monthly schizophrenia injection
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
